Literature DB >> 15324700

Species- and cell type-specific requirements for cellular transformation.

Annapoorni Rangarajan1, Sue J Hong, Annie Gifford, Robert A Weinberg.   

Abstract

Recent evidence suggests that human cells require more genetic changes for neoplastic transformation than do their murine counterparts. However, a precise enumeration of these differences has never been undertaken. We have determined that perturbation of two signaling pathways-involving p53 and Raf-suffices for the tumorigenic conversion of normal murine fibroblasts, while perturbation of six pathways-involving p53, pRb, PP2A, telomerase, Raf, and Ral-GEFs-is needed for human fibroblasts. Cell type-specific differences also exist in the requirements for tumorigenic transformation: immortalized human fibroblasts require the activation of Raf and Ral-GEFs, human embryonic kidney cells require the activation of PI3K and Ral-GEFs, and human mammary epithelial cells require the activation of Raf, PI3K, and Ral-GEFs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324700     DOI: 10.1016/j.ccr.2004.07.009

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  204 in total

Review 1.  Stem cells in the human breast.

Authors:  Ole William Petersen; Kornelia Polyak
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

Review 2.  The Exocyst at a Glance.

Authors:  Bin Wu; Wei Guo
Journal:  J Cell Sci       Date:  2015-08-03       Impact factor: 5.285

Review 3.  Friend or foe? Telomerase as a pharmacological target in cancer and cardiovascular disease.

Authors:  Karima Ait-Aissa; Johnathan D Ebben; Andrew O Kadlec; Andreas M Beyer
Journal:  Pharmacol Res       Date:  2016-07-06       Impact factor: 7.658

4.  Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi complex are dispensable for proliferation and transformation.

Authors:  David Matallanas; Victoria Sanz-Moreno; Imanol Arozarena; Fernando Calvo; Lorena Agudo-Ibáñez; Eugenio Santos; María T Berciano; Piero Crespo
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

5.  Interaction of the oncogenic miR-21 microRNA and the p53 tumor suppressor pathway.

Authors:  Xiaodong Ma; Saibyasachi N Choudhury; Xiang Hua; Zhongping Dai; Yong Li
Journal:  Carcinogenesis       Date:  2013-02-05       Impact factor: 4.944

6.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

Authors:  Nabeel Bardeesy; Andrew J Aguirre; Gerald C Chu; Kuang-Hung Cheng; Lyle V Lopez; Aram F Hezel; Bin Feng; Cameron Brennan; Ralph Weissleder; Umar Mahmood; Douglas Hanahan; Mark S Redston; Lynda Chin; Ronald A Depinho
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.

Authors:  Pietri Puustinen; Melissa R Junttila; Sari Vanhatupa; Anna A Sablina; Melissa E Hector; Kaisa Teittinen; Olayinka Raheem; Kirsi Ketola; Shujun Lin; Juergen Kast; Hannu Haapasalo; William C Hahn; Jukka Westermarck
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 8.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

9.  CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation.

Authors:  David M Burns; Joel D Richter
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

Review 10.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.